SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trading significantly lower following reports that merger discussions with Merck have collapsed due to disagreements over valuation. Despite the immediate sell-off, community sentiment remains split between investors bracing for further downside and those viewing the dip as a long-term entry point given the company's strong clinical data in RAS-targeted oncology.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

HYPE is currently trending due to its surge in institutional interest and significant trading volume, as it establishes itself as a leader in decentralized perpetual futures. The community is actively discussing its record-breaking fee buybacks, the anticipation of new crypto-related regulatory developments, and its role as a high-performance alternative to traditional assets.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors digest the company's recent ASCO plenary presentation, which showcased compelling overall survival data for its ivonescimab lung cancer treatment. The community is heavily focused on the clinical implications of beating the current standard of care and the company's path toward regulatory milestones, despite ongoing debates regarding clinical trial design and short-term volatility.

Taylor Morrison Home Corp. engages in the business of residential homebuilding and the development of lifestyle communities. It operates through the following segments: East, Central, West, and Financial Services. The East segment includes operations in Atlanta, Charlotte, Chicago, Orlando, Raleigh, Southwest Florida, and Tampa regions. The Central segment consists of Austin, Dallas, Denver, Houston, and Indianapolis. The West segment covers Bay Area, Las Vegas, Phoenix, Portland, Sacramento, Seattle, and Southern California. The Financial Services segment refers to Taylor Morrison Home Funding, Inspired Title Services, and Taylor Morrison Insurance Services. The company was founded in 1936 and is headquartered in Scottsdale, AZ.

Taylor Morrison Home Corp.

Taylor Morrison Home Corp. is in the spotlight following news of a proposed acquisition by Berkshire Hathaway, fueling significant community debate over the valuation and the broader implications for the homebuilding sector. Investors are closely monitoring the potential ripple effects of this deal on industry peers as sentiment shifts regarding housing affordability and market confidence.

Las Vegas Sands Corp. engages in the development of destination properties. It operates through the Macao and Singapore geographical segments. The Macao segment handles the operations of The Venetian Macao, The Londoner Macao, The Parisian Macao, The Plaza Macao and Four Seasons Macao, and Sands Macao. The Singapore segment includes the Marina Bay Sands. The company was founded by Sheldon Gary Adelson in August 2004 and is headquartered in Las Vegas, NV.

Las Vegas Sands Corp

Las Vegas Sands is seeing increased attention as the community weighs potential bull flag breakout setups against concerns over the company's reliance on the Macau market and internal leadership dynamics. Investors are actively debating the stock's long-term valuation, with many monitoring the balance between regional growth opportunities and the impact of the company's dividend and buyback programs.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

Hyperliquid Strategies is trending as the market prices in the potential for a gamma squeeze, fueled by its low float and persistent institutional buying pressure. Community discussion remains heavily focused on the stock's role as an asymmetric proxy for the HYPE token and broader decentralized finance infrastructure.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending as investors debate its long-term potential following a transition to a capped supply model, with community sentiment divided between those betting on a technical turnaround and critics who remain skeptical of its adoption metrics. Discussions are heavily focused on its future as an enterprise-grade network and the impact of upcoming upgrades on its ability to compete with other major blockchain ecosystems.

Safe Pro Group, Inc. engages in the provision and acquisition of security and protection products. Its products include Artificial Intelligence (AI) and Machine Learning (ML) software technology and photogrammetry analysis tools, bullet and blast resistant personal protection equipment, and aerial managed services and mission-critical uncrewed solutions. The firm operates through the following segments: Safe-PRO USA, Airborne Response, and Safe Pro AI. The company was founded by Daniyel Erdberg on December 15, 2021 and is headquartered in Aventura, FL.

Safe Pro Group Inc

Safe Pro Group Inc. is trending as the community highlights recent U.S. Army selection for combat training exercises and a series of high-growth revenue reports driven by its AI-powered battlefield threat detection technology. Investors are actively discussing the company's expanding defense contracts, recent strategic partnerships in the drone sector, and its potential as an under-the-radar AI defense play.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is trending as investors monitor an upcoming earnings release, focusing on whether the company can successfully stabilize customer acquisition costs following recent algorithm-driven volatility. Community sentiment remains polarized, with many traders attracted to the stock's significant discount and cash-rich balance sheet while remaining cautious about the potential for further near-term downside.

Zoracles

Zoracles is seeing active community discussion as investors debate its long-term potential against a backdrop of broader crypto market volatility and recent downward pressure. Many users are focusing on accumulation and the importance of patience, highlighting upcoming regulatory catalysts and platform utility as primary drivers for a potential recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?

Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss?

QIAGEN cuts its 2026 growth outlook after a Q1 miss, but margins, cash flow and a debt-free balance sheet could steady the narrative.

QIAGEN Business Breakdown and Growth Drivers for 2026

QGEN targets steadier growth through 2027, leaning on new launches, Connect automation and QIAstat-Dx menu expansion amid choppy demand.

Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific Orbitrap Tribrid Apex and Thermo Scientific Orbitrap Excedion mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific...

Is Thermo Fisher Scientific Inc. (TMO) a Buy as RBC Restarts Coverage With Sector Perform Rating?

Is Thermo Fisher Scientific Inc. (TMO) a Buy as RBC Restarts Coverage With Sector Perform Rating...

If You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today

Thermo Fisher Scientific Announces Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo...

Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the companys industry leadership and the essential role of its best-in-class...

Thermo Fisher Scientific Inc. (TMO) Unveils Bioprocess Design Center to Develop Life-Changing Therapies

Thermo Fisher Scientific Inc. (TMO) Unveils Bioprocess Design Center to Develop Life-Changing Therapies...

Terrestrial Energy Appoints Tyler Gronbach as Vice President of Investor Relations and Public Relations

Terrestrial Energy Inc. (Nasdaq: IMSR) (Terrestrial Energy or the Company), a developer of proprietary Generation IV small modular nuclear power plants, today announced that Tyler Gronbach has joined...

Thermo Fisher Scientific Inc. serves the scientific community through a broad offering of innovative products and services. Thermo Fisher Scientific serves customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and development, quality and process control settings. The company’s global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company continuously increases its depth of capabilities across its broad portfolio of innovative products and services and leverages its extensive global channels to address customers’ needs. The company does this through organic investments in research and development, capacity and capabilities and through acquisitions. The company’s goal is to enable its customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their challenges and advance their important work. The company’s history roots back to the year 1956 when the business was first established. Thermo Fisher Scientific was formed in 2006 from the merger of Thermo Electron and Fisher Scientific and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$5.72	--	--	N/A
Q1 '26	$5.25	$5.44	3.65%	BEAT
Q4 '25	$6.45	$6.57	1.88%	BEAT
Q3 '25	$5.50	$5.79	5.32%	BEAT
Q2 '25	$5.23	$5.36	2.56%	BEAT

TMO
Thermo Fisher Scientific Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Compact View

Latest TMO News

TMOThermo Fisher Scientific Inc.